7 Undervalued Health Care Providers & Services Stocks for Monday, November 18
Discover the top 7 undervalued Health Care Providers & Services stocks for Monday, November 18 based on AAII’s Stock Grades.Jenna Brashear
Stock Evaluator: P3 Health Partners Inc. (PIII)
P3 Health Partners Inc. PIII
$9.83
-0.39
-3.82%
July 31, 2026 4:00:00 PM
EST
Volume: 12,687
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Providers & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. The company was founded in 2020 and is based in Henderson, Nevada.
Commentary & Analysis
5 Undervalued Biotechnology & Medical Research Stocks for Friday, July 26
Discover the top 5 undervalued Biotechnology & Medical Research stocks for Friday, July 26 based on AAII’s Stock Grades.Omar Beirat
4 Undervalued Biotechnology & Medical Research Stocks for Thursday, June 13
Discover the top 4 undervalued Biotechnology & Medical Research stocks for Thursday, June 13 based on AAII’s Stock Grades.Grace Malone
4 Undervalued Biotechnology & Medical Research Stocks for Wednesday, March 06
Discover the top 4 undervalued Biotechnology & Medical Research stocks for Wednesday, March 06 based on AAII’s Stock Grades.Grace Malone
7 Undervalued Biotechnology & Medical Research Stocks for Tuesday, February 14
Discover the top 7 undervalued Biotechnology & Medical Research stocks for Tuesday, February 14 based on AAII’s Stock Grades.Jack Gilleland
Financial Summary
| Share Statistics | PIII | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $33.4 | $1,875.0 | 13% |
|
| Shares Out (Mil) | 8.4 | 77.1 | 19% |
|
| Institutional Ownership | 67.6% | 88.9% | 42% |
|
| Float (Mil) | 1.4 | 50.3 | 3% |
|
| Beta | 1.60 | 0.86 | 85% |
|
| Avg Daily Volume (000s) | 21 | 466 | 21% |
|
| Price Change (52-week) |
43.6% | 78.5% | 77% |
|
| Growth | PIII | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 24.3% | 10.9% | 86% |
|
| Net Income (5yr) | (36.3%) | (1.1%) | 11% |
|
| EPS (5yr) | (13.7%) | 3.0% | 19 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (25.0%) | (18.2%) | 25% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | PIII | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,472 | $1,464 | 56% |
|
| Net Income (TTM) (Mil) | ($126) | $15 | 9% |
|
| EPS (TTM) | ($38.536) | $0.300 | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($85) | $138 | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($15) | $7 | 28% |
|
| Long-Term Debt (Q1) (Mil) | $270 | $323 | 53% |
|
| Enterprise Value (Q1) (Mil) | $347 | $2,130 | 31% |
|
| Valuation | PIII | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.90 | na |
|
| P/E | na | 26.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | PIII | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (0.7%) | 27.6% | 4% |
|
| Net Margin | (8.6%) | 1.1% | 22% |
|
| ROA | (17.3%) | 1.8% | 22% |
|
| ROE | 309.2% | 6.9% | 99% |
|
| Liabilities to Assets | 119.8% | 60.0% | 96% |
|
| F-Score | 3 | 5 | 19% |
|
P3 Health Partners Inc. did not pass any screens on 7/30/2026.
